Results 1 to 10 of about 7,028 (198)

Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region [PDF]

Dermatology and Therapy
Introduction Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422 ...
Kilian Eyerich, Pedro Mendes-Bastos, Gregor Holzer, Vipul Jain, Norito Katoh, Paula C. Luna, Pablo Coto Segura, Michael Lane, Ayman Grada, Alvaro Moreira, Christopher G. Bunick   +10 more
doaj   +2 more sources

Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study [PDF]

RMD Open
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study.Methods Patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) were randomised to placebo ...
Filip van den Bosch, Roy Fleischmann, Patrick Durez, Yoshiya Tanaka, Charles Peterfy, Ricardo Blanco, Eduardo Mysler, Louis Bessette, Jerzy Swierkot, Sebastian Meerwein, Diane Caballero, Duke Geem, Lingfeng Luo, Lauren D Smith   +13 more
doaj   +2 more sources

Upadacitinib: Mechanism of action, clinical, and translational science [PDF]

Clinical and Translational Science
Upadacitinib is a selective Janus kinase (JAK) inhibitor which is approved by the US Food and Drug Administration, the European Medicines Agency, as well as other agencies around the world for the treatment of several chronic inflammatory diseases ...
Mohamed‐Eslam F. Mohamed, Sumit Bhatnagar, Julie M. Parmentier, Priscila Nakasato, Peter Wung   +4 more
doaj   +2 more sources

Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients [PDF]

RMD Open
Objectives To evaluate the effectiveness and safety of upadacitinib in treatment-refractory inflammatory myositis.Methods Patients with refractory inflammatory myositis treated with upadacitinib from a single urban centre in Vancouver, British Columbia ...
Kun Huang, Jan Dutz, Madelaine Beckett
doaj   +2 more sources

Treatment of atopic dermatitis with upadacitinib: adcare single center experience [PDF]

Frontiers in Medicine
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina, Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Mar’yana A. Lysenko, Luis Felipe C. Ensina   +15 more
doaj   +3 more sources

Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease [PDF]

RMD Open
Objectives Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk.Methods In SELECT-COMPARE, patients received upadacitinib ...
Roy Fleischmann, Stephen Hall, Gerd R Burmester, Eduardo Mysler, Peter Taylor, Tianming Gao, Sander Strengholt, Bettina Wick-Urban, Andrew Garrison, Irina Fish   +9 more
doaj   +3 more sources

Intensified Upadacitinib Dosing for Adolescent Patients with Acute Severe Ulcerative Colitis [PDF]

Children
Background/Objectives: In adolescent patients with ulcerative colitis refractory to anti-tumor necrosis factor (TNF) therapy, episodes of acute severe ulcerative colitis (ASUC) require hospitalization or surgery. Upadacitinib can be a potential colectomy-
Perseus V. Patel, Martina Rigmaiden, Alka Goyal, Rachel Bensen, Dorsey Bass, Jonathan Moses, Michael J. Rosen, Ruben J. Colman   +7 more
doaj   +2 more sources

Upadacitinib for the treatment of radiographic axial spondyloarthritis — case series and review of the literature [PDF]

Drugs in Context
Upadacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of different rheumatic diseases, including axial spondyloarthritis (axSpA).
Giuseppe Lopalco, Arianna D’Antonio, Maria Sole Chimenti, Florenzo Iannone   +3 more
doaj   +3 more sources

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series [PDF]

Journal of Dermatological Treatment, 2023
Purpose: The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating ...
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo, Alessandra Narcisi   +6 more
doaj   +2 more sources

Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting [PDF]

Rheumatology and Therapy
Introduction This study aimed to compare the real-world effectiveness of upadacitinib vs. other Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA). Methods Data were extracted from the Adelphi RA Disease Specific Programme™ (DSP),
Peter C. Taylor, Aditi Kadakia, Jack Milligan, Ana Romero, Oliver Howell, Pankaj A. Patel, Sophie Barlow, Roberto Caporali   +7 more
doaj   +2 more sources